Surprisingly, in both the Brca1- and Brca2-deficient tumour models used in this study, the in vivo treatment with anti-PD-L1, whether as a monotherapy or in combination with olaparib, resulted in a systemic increase in nearly all the studied immune cells presenting surface PD-L1. Here, BRCA2 is linked to neoplasm.